Alzheimer's disease, metal ions and metal homeostatic therapy

Trends in Pharmacological Sciences

Volumn 30, Issue 7, 2009, Pages 346-355

  Zatta, Paolo ^a   Drago, Denise ^a   Bolognin, Silvia ^a   Sensi, Stefano L ^b,c  

^a CNR   (Italy)

^b CeSI Center for Excellence on Aging   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN; CLIOQUINOL; COPPER; CUPRIC ION; IRON; METAL ION; PBT 2; QUINOLONE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG; ZINC ION; ZINC TRANSPORTER;

ALZHEIMER DISEASE; ARTICLE; CELL LOSS; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; HOMEOSTASIS; HUMAN; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; CLIOQUINOL; HOMEOSTASIS; HUMANS; METALS; PLAQUE, AMYLOID;

EID: 67649392464     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.05.002     Document Type: Article

References (116)

1. Liu G., et al. Metal exposure and Alzheimer's pathogenesis. J. Struct. Biol. 155 (2006) 45-51
2. Zatta P., et al. The role of metals in neurodegenerative processes: aluminum, manganese, and zinc. Brain Res. Bull. 62 (2003) 15-28
3. Bouras C., et al. A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Eur. Neurol. 38 (1997) 53-58
4. Crouch P.J., et al. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J. 274 (2007) 3775-3783
5. Good P.F., and Perl D.P. Aluminium in Alzheimer's?. Nature 362 (1993) 418
6. Lovell M.A., et al. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann. Neurol. 33 (1993) 36-42
7. Lovell M.A., et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 (1998) 47-52
8. Perl D.P., and Brody A.R. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208 (1980) 297-299
9. Adlard P.A., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59 (2008) 43-55
10. Cherny R.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
11. Opazo C., et al. Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals 16 (2003) 91-98
12. Bush A.I., and Tanzi R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5 (2008) 421-432
13. Ha C., et al. Metal ions differentially influence the aggregation and deposition of Alzheimer's β-amyloid on a solid template. Biochemistry 46 (2007) 6118-6125
14. Frederickson C.J., and Moncrieff D.W. Zinc-containing neurons. Biol. Signals 3 (1994) 127-139
15. Frederickson C.J., et al. Distribution of histochemically reactive zinc in the forebrain of the rat. J. Chem. Neuroanat. 5 (1992) 521-530
16. Sindreu C.B., et al. Boutons containing vesicular zinc define a subpopulation of synapses with low AMPAR content in rat hippocampus. Cereb. Cortex 13 (2003) 823-829
17. Frederickson C.J., et al. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 6 (2005) 449-462
18. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 26 (2003) 207-214
19. Lee J.Y., et al. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7705-7710
20. Lee J.Y., et al. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol. Aging 25 (2004) 1315-1321
21. Deshpande A., et al. A role for synaptic zinc in activity-dependent Aβ oligomer formation and accumulation at excitatory synapses. J. Neurosci. 29 (2009) 4004-4015
22. Lovell M.A., et al. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. J. Neuropathol. Exp. Neurol. 65 (2006) 489-498
23. Bush A.I., and Tanzi R.E. The galvanization of β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7317-7319
24. Atwood C.S., et al. Characterization of copper interactions with alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid β1-42. J. Neurochem. 75 (2000) 1219-1233
25. Mantyh P.W., et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem. 61 (1993) 1171-1174
26. Crouch P.J., et al. Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol. 40 (2008) 181-198
27. Opazo C., et al. Metalloenzyme-like activity of Alzheimer's disease β-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277 (2002) 40302-40308
28. Adlard P.A., and Bush A.I. Metals and Alzheimer's disease. J. Alzheimers Dis. 10 (2006) 145-163
29. Bayer T.A., and Multhaup G. Involvement of amyloid β precursor protein (AβPP) modulated copper homeostasis in Alzheimer's disease. J. Alzheimers Dis. 8 (2005) 201-206
30. Yin K.J., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 26 (2006) 10939-10948
31. White A.R., et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842 (1999) 439-444
32. Zatta P., et al. In vivo and in vitro effects of aluminum on the activity of mouse brain acetylcholinesterase. Brain Res. Bull. 59 (2002) 41-45
33. Alfrey A.C., et al. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. 294 (1976) 184-188
34. Zatta P., et al. A fatal case of aluminium encephalopathy in a patient with severe chronic renal failure not on dialysis. Nephrol. Dial. Transplant. 19 (2004) 2929-2931
35. Alfrey A.C. Dialysis encephalopathy. Kidney Int. Suppl. 18 (1986) S53-S57
36. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J. Alzheimers Dis. 8 (2005) 171-182
37. Reusche E. Argyrophilic inclusions distinct from Alzheimer neurofibrillary changes in one case of dialysis-associated encephalopathy. Acta Neuropathol. 94 (1997) 612-616
38. Zatta P. Aluminum and Alzheimer's disease: a Vexata Questio between uncertain data and a lot of imagination. J. Alzheimers Dis. 10 (2006) 33-37
39. Gupta V.B., et al. Aluminium in Alzheimer's disease: are we still at a crossroad?. Cell. Mol. Life Sci. 62 (2005) 143-158
40. Landsberg J.P., et al. Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature 360 (1992) 65-68
41. Miller L.M., et al. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 155 (2006) 30-37
42. Perl D.P., and Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. J. Alzheimers Dis. 9 (2006) 291-300
43. Shin R.W., et al. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. J. Neurosci. 14 (1994) 7221-7233
44. Shin R.W., et al. Neurofibrillary pathology and aluminum in Alzheimer's disease. Histol. Histopathol. 10 (1995) 969-978
45. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
46. Lesne S., et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
47. Oddo S., et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281 (2006) 39413-39423
48. Naslund J., et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
49. LaFerla F.M., et al. Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci. 8 (2007) 499-509
50. Cleary J.P., et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
51. Townsend M., et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers. Ann. Neurol. 60 (2006) 668-676
52. Walsh D.M., et al. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39 (2000) 10831-10839
53. Oddo S., et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem. 281 (2006) 1599-1604
54. Gouras G.K., et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol 156 (2000) 15-20
55. Drago D., et al. Potential pathogenic role of β-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int. J. Biochem. Cell Biol. 40 (2008) 731-746
56. Ricchelli F., et al. Aluminum-triggered structural modifications and aggregation of β-amyloids. Cell. Mol. Life Sci. 62 (2005) 1724-1733
57. Banks W.A., et al. Aluminum complexing enhances amyloid β protein penetration of blood-brain barrier. Brain Res. 1116 (2006) 215-221
58. Drago D., et al. Comparative effects of Aβ(1-42)-Al complex from rat and human amyloid on rat endothelial cell cultures. J. Alzheimers Dis. 11 (2007) 33-44
59. Drago D., et al. Aluminum modulates effects of β amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res. 11 (2008) 861-871
60. Demuro A., et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
61. Aleardi A.M., et al. Gradual alteration of mitochondrial structure and function by β-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 37 (2005) 207-225
62. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
63. Wu W.H., et al. Sequestration of copper from β-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J. Biol. Chem. 283 (2008) 31657-31664
64. Malm T.M., et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting β-amyloid burden. J. Neurosci. 27 (2007) 3712-3721
65. Crouch P.J., et al. Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. Proc. Natl. Acad. Sci. U. S. A 106 (2009) 381-386
66. Moret V., et al. 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg. Med. Chem. Lett. 16 (2006) 3298-3301
67. White A.R., et al. Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 (2006) 17670-17680
68. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23 (2002) 1031-1038
69. Bolognin S., et al. Mutual stimulation of β-amyloid fibrillogenesis by clioquinol and divalent metals. Neuromolecular Med. 10 (2008) 322-332
70. Lannfelt L., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7 (2008) 779-786
71. Ritchie C.W., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
72. Aizenman E., et al. Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release. J. Neurochem. 75 (2000) 1878-1888
73. Hwang J.J., et al. Zinc and 4-hydroxy-2-nonenal mediate lysosomal membrane permeabilization induced by H2O2 in cultured hippocampal neurons. J. Neurosci. 28 (2008) 3114-3122
74. 2+ in ischemic neuronal injury. Curr. Mol. Med. 4 (2004) 87-111
75. Sensi S.L., et al. Altered oxidant-mediated intraneuronal zinc mobilization in a triple transgenic mouse model of Alzheimer's disease. Exp. Gerontol. 43 (2008) 488-492
76. 2+ pools. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6157-6162
77. Beckman K.B., and Ames B.N. The free radical theory of aging matures. Physiol. Rev. 78 (1998) 547-581
78. Mocchegiani E., et al. Zinc-bound metallothioneins as potential biological markers of ageing. Brain Res. Bull. 55 (2001) 147-153
79. Giacconi R., et al. Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform. Mech. Ageing Dev. 124 (2003) 371-378
80. Mocchegiani E., et al. The variations during the circadian cycle of liver CD1d-unrestricted NK1.1+TCR gamma/delta+ cells lead to successful ageing. Role of metallothionein/IL-6/gp130/PARP-1 interplay in very old mice. Exp. Gerontol. 39 (2004) 775-788
81. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
82. Hanger D.P., et al. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15 (2009) 112-119
83. Lovestone S., and Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78 (1997) 309-324
84. Mudher A., and Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 25 (2002) 22-26
85. Gotz J., et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science 293 (2001) 1491-1495
86. Lewis J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
87. 2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production. Proc. Natl. Acad. Sci. U. S. A 96 (1999) 2414-2419
88. Malaiyandi L.M., et al. Direct visualization of mitochondrial zinc accumulation reveals uniporter-dependent and -independent transport mechanisms. J. Neurochem. 93 (2005) 1242-1250
89. Maret W. The function of zinc metallothionein: a link between cellular zinc and redox state. J. Nutr. 130 (2000) 1455S-1458S
90. 2+ transported by the mitochondrial calcium uniporter?. FEBS Lett 356 (1994) 195-198
91. 2+ entry into cortical neurons induces mitochondrial Zn2+ uptake and persistent mitochondrial dysfunction. Eur. J. Neurosci. 12 (2000) 3813-3818
92. Aschner M. The functional significance of brain metallothioneins. FASEB J. 10 (1996) 1129-1136
93. Frederickson C.J., et al. Depletion of intracellular zinc from neurons by use of an extracellular chelator in vivo and in vitro. J. Histochem. Cytochem. 50 (2002) 1659-1662
94. + channels. Neuron 41 (2004) 351-365
95. Lee J.Y., et al. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp. Neurol. 184 (2003) 337-347
96. 2+ ions. J. Biol. Chem. 282 (2007) 16068-16078
97. Schlief M.L., et al. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J. Neurosci. 25 (2005) 239-246
98. Schlief M.L., et al. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14919-14924
99. White A.R., et al. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J. Neurosci 19 (1999) 9170-9179
100. Hesse L., et al. The β A4 amyloid precursor protein binding to copper. FEBS Lett. 349 (1994) 109-116
101. Bayer T.A., et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U. S. A 100 (2003) 14187-14192
102. Maynard C.J., et al. Overexpression of Alzheimer's disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277 (2002) 44670-44676
103. Ponka P., et al. Function and regulation of transferrin and ferritin. Semin. Hematol. 35 (1998) 35-54
104. Sipe J.C., et al. Brain iron metabolism and neurodegenerative disorders. Dev. Neurosci. 24 (2002) 188-196
105. Connor J.R., et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31 (1992) 327-335
106. Rao K.S., and Rao G.V. Aluminium leaching from utensils-a kinetic study. Int. J. Food Sci. Nutr. 46 (1995) 31-38
107. Moore P.B., et al. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement. Geriatr. Cogn. Disord. 11 (2000) 66-69
108. Whitehead M.W., et al. Mechanisms of aluminum absorption in rats. Am. J. Clin. Nutr. 65 (1997) 1446-1452
109. Amstrong R.A., et al. Aluminium administered in drinking water but not in the diet influences biopterin metabolism in the rodent. Biol. Chem. Hoppe Seyler 373 (1992) 1075-1078
110. Roskams A.J., and Connor J.R. Aluminum access to the brain: a role for transferrin and its receptor. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 9024-9027
111. Gerhart D.Z., et al. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am. J. Physiol. 273 (1997) E207-E213
112. Yokel R.A., et al. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood-brain barrier transport. Brain Res. 930 (2002) 101-110
113. Banks W.A., et al. Interactions of β-amyloids with the blood-brain barrier. Ann. N. Y. Acad. Sci. 826 (1997) 190-199
114. 14C]sucrose in rats. Brain Res. 569 (1992) 330-335
115. Yokel R.A. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J. Alzheimers Dis. 10 (2006) 223-253
116. Yokel R.A., et al. The distribution of aluminum into and out of the brain. J. Inorg. Biochem. 76 (1999) 127-132